The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
The investigational encapsulated cell therapy is designed to produce ciliary neurotropic factor continuously, thus changing the rate of disease progression in patients with macular telangiectasia type 2. The prespecified primary endpoint of the multicenter, randomized, sham-controlled studies was the implant’s impact on the rate of change in ellipsoid zone area loss from baseline